BioCardia, Inc. (BCDA): Revenue
$0
Year ended 2025-12-31
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $58.0K | -87.8% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $477.0K | -64.7% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $1.35M | +33.2% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $1.01M | +600.0% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $145.0K | -79.6% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $710.0K | +13.6% | 2021-03-30, From 2019-01-01 |
| 2018-12-31 | $625.0K | +30.5% | 2020-04-09, From 2018-01-01 |
| 2017-12-31 | $479.0K | -16.8% | 2020-04-09, From 2017-01-01 |
| 2016-12-31 | $576.0K | -36.3% | 2019-04-02, From 2016-01-01 |
| 2015-12-31 | $904.0K | n/a | 2018-03-16, From 2015-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | $0 | -100.0% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $237.26M | +726.7% |
| Amgen Inc (AMGN) | 2025-12-31 | $36.75B | +10.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $59.42M | +4.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
| Biogen Inc. (BIIB) | 2025-12-31 | $9.89B | +2.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $14.56M | +53.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $29.44B | +2.4% |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗